Exploring Alternatives to the Predominant Pharma Patent Model in the Global South and Impact of AI

The transformative spirit of the TRIPS Agreement was widely seen as an encouraging force driving a transnational change in the era of globalisation and the interconnectivity of trade.However, 30 years have passed since then, and a closer look at the evaluation of this agreement over the course of almost 30 years gives us significant questions to ponder over, albeit from a public policy perspective, and reconciling the same with the envisaged system of Intellectual Property rights that the agreement desired to regulate in the first place.The scope of the current research was aligned with TRIPS and the pharmaceutical sector, delineating the crucial junctures of monopoly of patents visà-vis public health, which is a broader concern or a social justice issue.While IP is a development vehicle pushing innovation and incentive as it churns out profits, it is needless to mention, after an extensive discussion on the interface of global south issues with the international instruments, that the balance needs to be established every time in IP operation and execution, especially when sensitive sectors like health come into the picture.This balance is not only a system of distribution that enables the disadvantaged to gain access they deserve and need, but also a regulatory system so that innovation can progress without hindering man's all-round development.Recent developments would also involve an investigation into how AI-driven technological boost can help in the process and what can be taken up in policy matters discussions.